Stockreport

Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat [Yahoo! Finance]

Akebia Therapeutics, Inc.  (AKBA) 
Last akebia therapeutics, inc. earnings: 3/10 07:49 am Check Earnings Report
US:NASDAQ Investor Relations: ir.akebia.com/investor-relations
PDF This expansion is centered on two primary product candidates: AKB-097, a next-generation complement inhibitor, and praliciguat, a soluble guanylate cyclase/sGC stimulato [Read more]